Pharma Company Avoids $50M Payment Obligation Over Cancer Drug
The Delaware Court of Chancery on Wednesday ruled that drugmaker Gilead Sciences Inc. can avoid a $50 million milestone payment to shareholders of a company it bought in 2011, finding that a drug it acquired from Calistoga Pharmaceuticals Inc. did not win the kind of broad approval needed to trigger the post-closing bonus.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now